FDA official notes possible cancer risk in diabetes drug Byetta

04/12/2010 | Bloomberg

An FDA official reported that injectable and once-weekly versions of diabetes drug Byetta "seem to give a similar signal" as cancer in mice that received Novo Nordisk's diabetes treatment Victoza. A representative of Eli Lilly and Co., which owns Byetta with Amylin Pharmaceuticals, said the once-weekly version's link to cancer risk "has not been established, but cannot be ruled out."

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care